Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Jul 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help diagnose Alzheimer’s disease using a blood test. Currently, doctors diagnose Alzheimer’s by testing fluid taken from around the spine (called cerebrospinal fluid) through a procedure known as a lumbar puncture or spinal tap. This fluid is checked for certain proteins linked to Alzheimer’s. The new test looks at a protein called p-Tau217 in the blood, which might provide similar information but in a simpler and less invasive way. The goal is to see if this blood test works as well as the traditional spinal fluid tests in helping doctors confirm Alzheimer’s disease.

The study will include about 150 patients aged 65 and older who are already visiting the memory center at CHU Amiens in France and are suspected of having Alzheimer’s disease. If a lumbar puncture is planned as part of their usual care, participants will also have a small blood sample taken during the same hospital visit to measure p-Tau217. The study will compare results from the blood test and spinal fluid tests to see how well they match the clinical diagnosis. People who are minors, pregnant, or under legal guardianship cannot join. This research could lead to easier, less uncomfortable testing for Alzheimer’s in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients addressed to the memory center of CHU Amiens with a clinical suspicion of AD, for whom lumbar puncture / CSF biomarkers of AD determination is proposed.
• Exclusion Criteria:
• • Minor patients
• • pregnant women
• • patients under guardianship